Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation

Haematologica

Volumn 94, Issue 8, 2009, Pages 1101-1108

  Schiffer, Joshua T ^a,b   Kirby, Kate ^a   Sandmaier, Brenda ^a,b   Storb, Rainer ^a,b   Corey, Lawrence ^a,b   Boeckh, Michael ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Respiratory virus; Stem cell transplantation

Indexed keywords

AMANTADINE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FLUDARABINE; IMMUNOGLOBULIN; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OSELTAMIVIR; RIBAVIRIN; RIMANTADINE; TACROLIMUS;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; ARTIFICIAL VENTILATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CHILD; CHRONIC LEUKEMIA; COHORT ANALYSIS; COMMUNICABLE DISEASE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN RHINOVIRUS; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INTERMETHOD COMPARISON; LOWER RESPIRATORY TRACT INFECTION; LUNG BIOPSY; LUNG LAVAGE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIXED INFECTION; MORTALITY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYELOMA; NONMYELOABLATIVE CONDITIONING; PARAINFLUENZA VIRUS 1; PARAINFLUENZA VIRUS 2; PARAINFLUENZA VIRUS 3; PARAINFLUENZA VIRUS 4; PARAINFLUENZA VIRUS INFECTION; PRESCHOOL CHILD; RADIATION DOSE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RETROSPECTIVE STUDY; SCHOOL CHILD; SOLID TUMOR; TREATMENT DURATION; VIRAL RESPIRATORY TRACT INFECTION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COMMON COLD; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LOGISTIC MODELS; MALE; MIDDLE AGED; PARAMYXOVIRIDAE INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, ISOGENEIC; VIRUS DISEASES; YOUNG ADULT;

EID: 68049142289     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2008.003186     Document Type: Article

References (26)

1. Ison MG, Hayden FG, Kaiser L, Corey L, Boeckh M. Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia. Clin Infect Dis 2003;36:1139-43.
2. Ljungman P. Respiratory virus infections in stem cell transplant patients: the European experience. Biol Blood Marrow Transplant 2001;7 Suppl:5S-7S.
3. Nichols WG, Gooley T, Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant 2001;7 Suppl:11S-5S.
4. Whimbey E, Englund JA, Couch RB. Community respiratory virus infections in immunocompromised patients with cancer. Am J Med 1997;102:10-8.
5. Whimbey E, Vartivarian SE, Champlin RE, Elting LS, Luna M, Bodey GP. Parainfluenza virus infection in adult bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 1993;12:699-701.
6. Harrington RD, Hooton TM, Hackman RC, Storch GA, Osborne B, Gleaves CA, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992;165:987-93.
7. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001;98:573-8.
8. Erard V, Chien JW, Kim HW, Nichols WG, Flowers ME, Martin PJ, et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis 2006;193:1619-25.
9. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531-6.
10. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-400.
11. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-63.
12. Fukuda T, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003;102:827-33.
13. Junghanss C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002;99:1978-85.
14. Buckner C, Clift R, Appelbaum F, Storb R, Fefer A, Petersen F, et al. Effects of treatment regimens on post marrow transplant relapse. Semin Hematol 1991 Jul;28 (Suppl 4):32-4.
15. Clift R, Buckner C, Thomas E, Bensinger W, Bowden R, Bryant E, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994;84: 2036-43.
16. Lynch M, Petersen F, Appelbaum F, Bensinger W, Clift R, Storb R, et al. Phase II study of busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies. Bone Marrow Transplant 1995;15: 59-64.
17. Boeckh M, Englund J, Li Y, Miller C, Cross A, Fernandez H, et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 2007;44:245-9.
18. Sorror M, Storer B, Maloney D, Sandmaier B, Martin P, Storb R. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008; 111:446-52.
19. Laport G, Sandmaier B, Storer B, Scott B, Stuart M, Lange T, et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant 2008;14:246-55.
20. Rezvani A, Storer B, Maris M, Sorror M, Agura E, Maziarz R, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 2008;26: 211-7.
21. Georges G, Maris M, Maloney D, Sandmaier B, Sorror M, Shizuru J, et al. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. Biol Blood Marrow Transplant 2007;13:423-32.
22. Gutman JA, Peck AJ, Kuypers J, Boeckh M. Rhinovirus as a cause of fatal lower respiratory tract infection in adult stem cell transplantation patients: a report of two cases. Bone Marrow Transplant 2007;40: 809-11.
23. Maris M, Boeckh M, Storer B, Dawson M, White K, Keng M, et al. Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. Exp Hematol 2003;31:941-52.
24. Baron F, Storer B, Maris MB, Storek J, Piette F, Metcalf M, et al. Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006; 12:1176-87.
25. Boeckh M, Berrey M, Bowden R, Crawford S, Balsley J, Corey L. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis 2001;184:350-4.
26. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000;49:1-125.